COBRE Center for Cancer Research Development

描述（由申请人提供）：这一修订后的竞争性更新建立在COBRE癌症研究发展中心（CCRD）成功指导有前途的初级研究人员走向独立的基础上。外部咨询和高级教师指导和咨询委员会（EAC和SFMAC）将在指导初级研究人员方面发挥重要作用。蛋白质组学和分子病理学核心将继续提供先进的技术和专家指导，资产，提高竞争力的校外基金。认识到罗得岛的癌症死亡率很高，CCRD将继续支持GI癌症领域的假设驱动研究。专注于肝/胃肠道癌症干细胞的新合作努力的发展将由研究发展委员会监督。这个主题将充分利用罗得岛医院已经在进行的强大的肝脏和干细胞研究项目。五个有才华的研究人员与重叠的研究兴趣将产生机会分享的想法和富有成效的互动。Chin博士将研究乙酰化依赖性STATS信号通路在人类和大鼠肝细胞癌中癌症干细胞自我更新和转移中的作用。Chatterjee博士是一名研究人员，他在第5年加入CCRD，将专注于raf激酶抑制蛋白（RKIP），这是一种对化疗敏感的潜在生物标志物，也是STAT 3介导的人类结肠癌转移的抑制剂。Sanders博士是一名新的研究人员，他将研究从胎儿和成人肝脏中分离的双能肝祖细胞的促有丝分裂信号传导表型，以及这些途径如何受到成人肝脏微环境的影响。另一位新的研究者Altura博士将研究乙酰化在生存素作为细胞分裂调节剂和凋亡抑制剂的定位、二聚化和活性中所起的作用。莫斯博士是CCRD支持的研究人员，他的第一个R 0 l将从事一项以gastrokine-1/2为中心的新研究，这是他在COBRE资助的第一个周期中发现的两种新型肿瘤抑制基因。虽然扩大基础癌症研究将继续是CCRD的主要使命，但我们将通过CCRD之友努力增加筹款活动，并扩大旨在提高公众对癌症研究价值的认识的外联活动。通过由临床观察驱动的创新项目促进基础科学家和临床肿瘤学家之间的互动也将是一个高度优先事项。在今后5年中，社区发展委员会将扩大其领导作用，与州和联邦立法者和政策制定者保持对话。CCRD将提供过渡到NCI指定的临床癌症中心所需的基础研究框架。 公共卫生相关性（由申请人提供）：CCRD将通过创造一个支持性的研究环境，促进有前途的科学家转变为独立研究者，促进基础癌症研究的扩展。CCRD将配备大量独立研究人员，通过由临床观察驱动的创新项目，建立临床和基础科学家之间的互动，为NCI指定的临床癌症中心建立所需的框架。CCRD将继续赞助旨在提高公众对癌症研究益处的认识的外展活动。

DESCRIPTION (provided by applicant): This revised competing renewal builds on the success of the COBRE Center for Cancer Research Development (CCRD) in guiding promising junior investigators towards independence. The External Advisory and Senior Faculty Mentoring and Advisory Committees (EAC and SFMAC) will play essential roles in mentoring of junior investigators. The Proteomics and Molecular Pathology Cores will continue to provide advanced technologies and expert guidance, assets that enhance competitiveness for extramural funds. Recognizing the high cancer mortality in Rhode Island, CCRD will continue to support hypothesis driven research in the area of Gl Cancer. Development of new collaborative endeavors focused on stem cells in liver/GI cancer will be overseen by a Research Development Committee. This theme will take full advantage of the strong liver and stem cell research programs already ongoing at Rhode Island Hospital. Five talented investigators with overlapping research interests will generate opportunities for sharing of ideas and productive interaction. Dr. Chin will examine the role of acetylation dependent STATS signaling pathways in self-renewal and metastasis of cancer stem cells in human and rat hepatocellular carcinomas. Dr. Chatterjee, an investigator who joined CCRD in year 5, will focus on raf kinase inhibitory protein (RKIP), a potential biomarker for susceptibility to chemotherapy and an inhibitor of STAT3 mediated metastasis of human colon cancer. Dr. Sanders, a new investigator, will examine the mitogenic signaling phenotype of bipotent hepatic progenitors isolated from fetal and adult liver and how these pathways are influenced by the adult liver microenvironment. Dr. Altura, another new investigator, will examine the role that acetylation plays in the localization, dimerization and activity of survivin as a regulator of cell division and an inhibitor of apoptosis. Dr. Moss, a CCRD supported investigator with his first R0l, will pursue a new line of research centered on gastrokine-1/2, two novel tumor suppressor genes identified during his first cycle of COBRE funding. Although expanding basic cancer research will continue to be the primary mission of CCRD, we will work through the Friends of CCRD to increase fundraising efforts and augment outreach activities aimed at increasing public awareness of the value of cancer research. Fostering interactions between basic scientists and clinical oncologists through innovative programs driven by clinical observation will also be a high priority. During the next 5 years, CCRD will expand its leadership role in sustaining a dialogue with State and Federal legislators and policy makers. CCRD will provide the basic research framework needed for transitioning into an NCI designated clinical cancer center. PUBLIC HEALTH RELEVANCE (provided by applicant): CCRD will promote the expansion of basic cancer research by creating a supportive research environment that facilitates the transition of promising scientists into independent investigators. Armed with a critical mass of independent investigators, CCRD will build framework needed for an NCI designated Clinical Cancer Center by forging interactions between clinical and basic scientists through innovative programs driven by clinical observations. CCRD will continue to sponsor outreach activities aimed at increasing public awareness of benefits derived from cancer research.